More than 145 European hematopoietic SCT programs have received JACIE (Joint Accreditation Committee for ISCT Europe and EBMT) accreditation since 2000, demonstrating compliance with FACT (Foundation for the Accreditation of Cell Therapy)-JACIE international standards. The association of JACIE with improved patient outcome was recently documented. However, conditions in which quality management systems were introduced and the actual benefits remain to be fully evaluated. Our study focuses on one aspect of quality management: introduction and use of indicators. Through a questionnaire sent to JACIE-accredited centers and responses from 32 programs (or 40%), we identified 293 indicators, including 224 (76%) that were introduced during the preparatory phase of JACIE accreditation. Indicators were associated with the following processes: measurement, analysis and improvement (54/293 or 18%); donor collection (49/293 or 16%); processing and storage of cell therapy products (37/293 or 12.5%); and administration of hematopoietic progenitor cells (67/293 or 23%). Mapping revealed an uneven distribution of indicators across the different subprocesses that contribute to this highly specialized medical procedure. Moreover, we found that only 101/293 indicators (34%) complied with the rules for implementation of a quality indicator, as defined by the FDX 50-171 standard. This suggests that risks to donors/recipients are unevenly monitored, leaving critical medical steps with low levels of monitoring.
INTRODUCTION
Following the publication of several reports on patients' safety 1, 2 and under increasing pressure from regulatory agencies, the healthcare community has started to introduce quality and risk management in hospital practices. It is expected that stringent and better control of conditions in which medical procedures are carried out will contribute to harmonizing medical practices, improve patient outcome, improve hospital logistics and reduce indirect costs associated with iatrogenic events. Quality indicators are increasingly being used in health care to support and document improvements and risk management. The purpose of implementing quality indicators is to periodically report and monitor data in order to evaluate organizations or practices. Different categories of indicators as defined by agencies issuing standards and regulations are used in health care; the most widely used are related to activity, outcome or process.
Autologous and allogenic hematopoietic SCT represent two examples of highly sophisticated medical procedures, with major applications in hematology and oncology. 3, 4 They take place in a challenging environment, designed to treat pediatric or adult patients with life-threatening congenital or acquired disorders. The procedure is associated with substantial morbidity and mortality, and novel approaches to reduce its toxicity are warranted. [5] [6] [7] [8] Although health authorities and regulatory agencies have enforced more and more stringent rules for inspection and authorization of activities in the field, these regulations differ from one country to another and mostly target processing facilities as being responsible for the production and delivery of therapeutic cells; it is largely unconcerned with the other partners-clinical and collection activities-as well as the interactions between the different components of the hematopoietic SCT program. Additionally, the increasing use of unrelated donors and cord blood units has fostered international exchanges of cell therapy products (CTPs), with the need for improved harmonization in these practices. 9, 10 The hematopoietic SCT medical community has responded to this situation with the design of an accreditation system that includes quality management 11 called FACT (Foundation for the Accreditation of Cell Therapy, http://factwebsite.org) in the US and Canada, where it was first established in 1996, and JACIE (Joint Accreditation Committee for ISCT Europe and EBMT, http:// www.jacie.org) in Europe, where it was established soon thereafter in 1999. 12, 13 These programs are the first of their kind in clinical medicine. The goal of FACT and JACIE is to promote excellence and harmonization of hematopoietic SCT, and this is achieved by measuring the compliance of candidate programs with a comprehensive set of international standards that cover the three major areas of the activity (clinical, collection and processing) as well as their interactions with external resources. FACT and JACIE have successfully established the organizations needed to carry out the accreditation process for the benefit of a large number of hematopoietic SCT programs in North America, Europe and elsewhere (the complete list of JACIE-accredited centers appears at http://www.jacie.org). Applications from hematopoietic SCT programs for accreditation have emerged at varying rates in the US and European countries, depending on internal motivation and the pressure that was imposed upon hospitals either by health authorities or by health-care payers. 14, 15 Whereas the hypothesis that implementation of a quality management system can truly improve patient outcome remains to be definitively demonstrated, a recently published retrospective analysis of the EBMT (European Group of Blood and Marrow Transplantation) file of European transplanted patients supports this view, with a stepwise improvement in the outcome of individuals transplanted in the context of a JACIE-accredited HSCT program, as compared to programs that have not engaged in the preparation of JACIE accreditation. 16 Together with the introduction of medical innovations and the accumulated experience of medical teams in charge of patients, the introduction of quality management may thus contribute to improve hematopoietic SCT outcome. 17 However, conditions in which quality management is introduced in medical care have not been fully evaluated, and whether or not sufficient resource and expertise has been allocated remains an issue. As an example, most common deficiencies reported by JACIE inspectors are in relation to the quality management system. 18, 19 The toolbox for quality management includes the reporting of unexpected results and adverse events, internal and external audits, and indicators. The aims of our study were the following: (i) to identify the number and nature of indicators that were implemented by French and other European hematopoietic SCT programs in the course of JACIE preparation, (ii) to understand whether a method was used to implement them and (iii) to assess if all the HSCT processes were efficiently monitored.
MATERIALS AND METHODS

Surveyed programs
In a first step, between April and October 2009, 14 French JACIE-accredited hematopoietic SCT programs registered with the 'Socié té Franc¸aise de Greffe de Moelle & de Thé rapie Cellulaire' (SFGM-TC; http://www.sfgm-tc. com) were contacted to participate in the survey through 21 individuals acting as program director, medical director or quality manager for each component of the program (clinical, collection and processing); the need to contact one or several individuals reflects the different organizations of hematopoietic SCT programs that draw on resources from different institutions/departments to conduct their activities.
In a second step, the study was extended to all other European JACIEaccredited hematopoietic SCT programs (located in Austria, Belgium, Czech Republic, Finland, Germany, Italy, Netherlands, Spain, Switzerland and United Kingdom). Between April and June 2010, a total of 68 programs were invited to complete the questionnaire through contacts with 79 individuals identified with the help of the JACIE accreditation office.
Questionnaire
In the first step, an internet-based questionnaire was created in French and made accessible through a secure website (http://www.wysuforms.com). For the second step, the same questionnaire was translated from French to English, integrated in an Excel worksheet and e-mailed to non-French JACIE-accredited European hematopoietic SCT programs by the JACIE office. The survey objectives were to collect information on indicators covering the safety of CTPs, the quality of patient care, and the organizational and economical aspects of the activity. The questionnaire was meant to identify indicators that were set up or used during the preparation of the JACIE accreditation with the purposes of categorizing these indicators, measuring the frequency with which identical or similar indicators were used by different hematopoietic SCT programs (redundancy), and evaluating the extent to which all processes (including management, operating as well as biomedical activities relating to clinical, collection or processing, and support) were covered. Respondents were invited to provide a brief description of each indicator, including the date of implementation, purpose and category (process, outcome or activity). In addition, they were asked to provide their own evaluation of the practicality and utility of each indicator in providing relevant information, the use (or pre-existence to JACIE) of each indicator for an authorization or certification/accreditation approach other than JACIE (national or international regulations, ISO, EFI, others) and the reliability of the definition and collection method of each indicator. The full questionnaire appears in (Supplementary Appendix 1).
Between October and December 2010, an additional questionnaire (Supplementary Appendix 2) was sent by e-mail to all respondents, in order to complete the initial description of the indicator implementation, with the guidance contained in the nomenclature established by the French Agency for Standardization ('Agence Franc¸aise de Normalisation', AFNOR; http://www.afnor.org; FDX 50-171 document). 20 Coverage of hematopoietic SCT processes All declared indicators were reviewed by the investigators, with the following goals: (i) to measure the extent to which identical or similar indicators were used by several hematopoietic SCT programs (redundancy) (Supplementary Table 1 ), (ii) to map each indicator implemented for JACIE or other quality approaches to the different subprocesses that contribute to the delivery of hematopoietic SCT. Figure 1 provides an overview of the indicators implemented for JACIE.
The general description of hematopoietic SCT activities is shared by many programs and largely borrows from standards such as ISO 9001 by identifying three major types of processes: management, operating and support. The management processes include the definition of an organization policy and strategy, and the steering of actions taken to achieve the organization goals. Operating processes are highly specific to the activity; they cover all medical and technical activities that are necessary for the delivery of hematopoietic SCT, ensuring donor and patient safety and satisfaction. The three most critical processes are identified in the JACIE standards (clinical, collection and processing). In addition, each of the processes was associated with one field or area of application: quality of patient care or safety of the CTP; very few indicators were used to monitor economical and logistical aspects of the activity, and this aspect will not be further discussed here. In some instances, the link with either of the two major fields or areas was obvious (donor selection and evaluation, donor follow-up and so on), while in others (such as CTP collection and administration), a link with both fields would be established. Supportive processes provide the necessary resources (training, communication, infrastructure, purchasing and so on) to conduct the main activity.
Categorization of indicators
Each identified indicator was ascribed to one of the following three types of measures used in quality management: 'activity', an indicator that measures the level of activity; 'process', an indicator that measures how the system works; or 'outcome', an indicator that measures the final product or result, including customer/patient/donor/healthcare satisfaction.
RESULTS
Many accredited programs use identical or similar indicators (redundancy)
Fourteen French JACIE-accredited programs represented by 21 individuals were contacted in the first phase of the survey (in several instances, there was more than one individual who answered for the same JACIE-accredited program, because the clinical, collection and processing tasks were carried over at different institutions). Responses were obtained from 12 programs, of which one could not be used due to paucity of information; finally, responses were evaluable from 11 out of 14 or 80% of the solicited French programs. This first phase of the study allowed for a validation of the questionnaire that was next translated and extended to other European programs.
During the second phase of the survey, 68 European and nonFrench JACIE-accredited programs represented by 79 individuals were contacted. Responses were obtained from 21 programs out of 68 or 30% of the solicited programs.
In total, we received responses from 44 out of 100 individuals who were sent our questionnaire; respondents were mainly clinical program directors, collection facility directors, processing facility directors and quality managers. Respondents are listed in the legend and their distribution by country of origin appears in Supplementary Figure 1 .
Two-hundred and ninety-three indicators were collected (Supplementary Table 1 ). A minority (25/293 or 8.5%) were descriptive statistics, such as numbers of hematopoietic SCT split by cell source (BM, apheresis and cord blood). Responders associated 102 indicators (35%) with the safety of the CTP, 172 (59%) with the quality of patient care and 19 (6.5%) with organizational and economical aspects of their activities. Four out of 32 programs declared indicators that covered only one area of application (quality of patient care), 21 out of 32 declared indicators that covered two areas (quality of patient care and safety of the CTP) and 7 out of 32 declared indicators associated with all three areas, including organizational and economical aspects (as defined in column 2 of the European questionnaire that appears in Supplementary data 1). Identical or similar indicators were implemented in approximately half of the programs; these include TRM (18/32 or 53%), numbers reporting severe adverse events (16/32 or 47%), microbial contamination during processing and patient satisfaction (11/32 or 34%).
Mapping indicators reveals an uneven distribution across processes that interact for the delivery of hematopoietic SCT Next, we mapped indicators across the different processes that are typically at work within a hematopoietic SCT program. Figure 1 illustrates the uneven distribution of indicators across the different processes that interact within the 33 JACIE-accredited European programs. Reported indicators are most often associated with the following processes: measurement, analysis and improvement (54 indicators, 18%); donor collection (49 indicators, 16%); processing and storage of CTPs (37 indicators, 12.5%) and administration of hematopoietic progenitor cells (67 indicators, 23%). Conversely, several at-risk operating processes described P a t i e n t t r a n s p l a n t e d P a t ie n t t o b e t r a n s p la n t e d , with the central horizontal line illustrating the main operating processes that contribute to donor and recipient care, the top line illustrating management processes, and the bottom line illustrating supportive processes (including human resource, training, infrastructures and so on). The pink color denotes processes that mainly deal with quality of patient care, while the green color denotes processes that mainly deal with safety of CTPs; the mixed color denotes a process that contributes to both objectives. A code has been attributed for each process, allowing for an association with every quality indicator (see also Supplementary Table 1 ). Indicators that were identified in the course of the survey described in this report were then mapped to one or several of the processes depicted on this diagram. The 'density' of indicators that appear on each process provides an indication of the proportion of the 32 surveyed JACIE-accredited programs that use similar or comparable indicators. The distribution of recorded indicators is obviously unequal across the many processes that interact for the production of hematopoietic SCT. As an example, it appears that indicators that monitor such critical processes as establishing the indication for hematopoietic progenitor cell (HPC) transplantation, donor selection and evaluation, donor follow-up or administration of conditioning regimen were infrequently reported. In addition, the diagram provides information with regard to indicators being set in place before (') or during (n) the JACIE accreditation preparation.
in the JACIE standards are rarely associated with indicators: this is the case for the decision-making process for hematopoietic SCT indication, pre-transplant patient evaluation, conditioning regimen and donor follow-up. Most indicators (224/293 or 76%) that were identified during this survey were established during the preparation of the JACIE accreditation (and appear as m in Figure 1 ). The 69 others had been in use since the implementation of quality management systems such as imposed by laws and regulations, or included in the ISO standards, and are in relation with collection, processing and administration of CTPs (and appear as ' in Figure 1 ).
Categorization of indicators
Splitting the collected indicators into the three above-described types: 'activity', 'process' and 'outcome', reveals that few reported indicators fell in the first category (25/293 or 8.5%). 'Outcome' and 'process' indicators, respectively, represent 139/293 (47%) and 129/293 (44%). There is again an uneven distribution of the various types of indicators across the different processes, as illustrated in Figure 2 . 'Process' indicators are mainly used for management, collection and processing processes, while 'outcome' indicators are mainly used to monitor clinical processes (transplantation, patient follow-up and patient satisfaction).
Moreover, while respondents considered most-declared indicators as reliable (270 or 92%), analysis of responses provided to the additional questionnaire that appears in Supplementary Appendix 2 showed that only 101/293 or 34% were compliant with the criteria contained in the AFNOR recommendations.
DISCUSSION
The FACT and JACIE quality management programs and standards were established in North America and Europe, respectively, in part as a response to the observation that errors could occur even at experienced medical institutions in the context of longestablished hematopoietic SCT programs. Since 2000 and the first accreditation of a European hematopoietic SCT program, more than 145 inspected centers have achieved JACIE accreditation at least once, and 32 centers have achieved re-accreditation in Europe. In 2009, we launched a survey of 82 programs that were holding a valid accreditation, starting with French centers, and then extending to accredited programs in other European countries. The objectives of this survey were to understand how the use of indicators could contribute to running and monitoring daily operations as well as the quality management system in place, and to determine whether all the HSCT processes were monitored.
The response rate was high among French JACIE-accredited centers, denoting both the interest of surveyed center representatives, and the good communication through the channel of the national scientific society: SFGM-TC. It was significantly lower in the second part of the survey targeting other European programs, likely as the result of the mode of communication between the for HPC transplantation P a t i e n t t o b e t r a n s p l a n t e d Patient's follow up P a t i e n t t r a n s p l a n t e d
Customer's satisfaction Quality management in hematopoietic SCT O Caunday et al JACIE executive office and accredited centers. Ultimately, the number of answers was high enough to provide a valid representation of the surveyed aspect of quality management systems, although it may favor programs with the highest level of engagement in the preparation and maintenance of JACIE accreditation. The limits are those of an auto-questionnaire that cannot guarantee an exhaustive listing of the indicators used, such as could have been collected by an on-site audit; quality managers and other professionals who supervise the preparation of JACIE accreditation may not comprehensively collect or use information regarding all aspects of the hematopoietic SCT program, for instance, pharmacy reports. Analysis of the declared indicators demonstrates that many of them are used by different programs, and that a minor, albeit significant, proportion was used prior to the preparation of JACIE, in the context of the preparation for authorizations such as those imposed upon cell therapy facilities by regulatory authorities, or in the context of voluntary certifications such as ISO 9001. Fifty-nine per cent of indicators relate to the quality of patient care, underlining the main objective pursued by medical teams. Thirty-five per cent of indicators relate to the risk and safety of CTPs; this is likely a consequence of the introduction of many regulations in this field by competent authorities. It is noteworthy that only a small proportion of declared indicators (6.5%) are used to measure efficiency in the production of care and the adjustment of resources to the activity. Although benefits to the patients are of utmost importance and standards were built to promote excellence rather than efficiency, costs dedicated to quality management and accreditation policies such as JACIE may also be offset with the demonstration of improved hospital logistics and organization.
Mapping of indicators implemented for JACIE, however, reveals an uneven distribution across the different processes that interact in the production of this highly specialized medical care (Figure 1) . The high proportion of these indicators that covers cell collection and cell-processing activities denotes again the fact that these two domains are tightly regulated by health authorities throughout Europe and the developed countries. Conversely, the low 'density' of declared indicators for certain areas of clinical activity is quite surprising, especially in view of the fact that errors in the administration of high-dose chemotherapy were among the reasons that triggered the establishment of FACT and JACIE. Although it is difficult to assess whether all indicators were declared for a given program, and some under-reporting may have occurred in the clinical field, it is unlikely to account for the gross lack of monitoring that our survey reveals. Although the roots of the problem may be well beyond the reach of JACIE and FACT, this suggests that educational efforts focused on health-care professionals who participate in clinical activities may be specifically needed. It is also surprising that only 20% of reporting programs had set an indicator on personnel training and re-training. Taken together, our observations are consistent with deficiencies that have been most commonly reported by JACIE inspectors (quality management, documentation, donor screening, CTP transportation). 18, 19 The uneven distribution between the three types of indicators over the different processes (Figure 2) suggests that weaknesses exist in the methodology used for the establishment of the quality management system, an observation consistent again with inspectors' reports. Theoretically, it is important to monitor all the steps of a process by using indicators. If that hypothesis was true in actual practice, the distribution of indicators across the different processes would have been more homogeneous. In order to produce improvements, a balance in the definition of the three types of indicators (activity, process and outcome) is strongly recommended. Although quality indicators are applied as a tool to guide the process of quality improvement in healthcare, hospitals that adopt quality indicators are faced with problems concerning implementation. 21, 22 Successful implementation, however, is critical to maximize the effect of quality indicators on the quality of care. 23 The need for additional training in implementation of indicators-and more generally all aspects of quality management and risk management-as an alternative to 'self-learning' for health-care professionals has been stressed in a previously published report. 24 The fact that many programs have stressed the difficulty in obtaining and maintaining human specialized and dedicated resources for quality management probably contributes to the observed defects; the goodwill of health-care professionals who usually have little or no training in quality management may not be sufficient to correct these issues. 22, 24 In conclusion, our study reveals the following: (i) a need for improved support and better methodology in the establishment of quality management to prepare accreditations in health care, such as JACIE, and (ii) the low level of monitoring of some critical processes contributing to the delivery of hematopoietic SCT, in part due to a different perception among diverse teams of what is a potential risk and grading of consequences associated with insufficient control of this risk. Risk management should be an ongoing part of the quality management process. A mechanism to review or monitor events should be implemented. Once a risk management process has been initiated, that process should continue to be used for events that might impact the original quality risk management decision, whether these events are planned (inspections, audits and so on) or unplanned (incident and adverse events report). Process mapping is a commonly used method to initiate a quality risk management process. 25 Future versions of the FACT-JACIE standards may usefully adopt such recommendations.
